Merck moves to drop drug after first of its kind EMA PRAC recommendation; CHMP opinion imminent
This article was originally published in SRA
Executive Summary
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has made its first recommendation on a safety referral procedure under the new EU pharmacovigilance legislation by calling for the suspension of a medicine for treating dyslipidemia1.